SmallCapsOnline Home





-- Access Pharmaceuticals -- ACTV -- Advanced Tissue Sciences, Inc. + Full Opinion 6-2-99 + Update 05-12-98 + Initial Opinion -- AMBI Inc. -- ARIAD Pharmaceuticals, Inc. -- Cell Therapeutics, Inc. -- CTC Communications -- Cubist Pharmaceuticals, Inc. -- Cypress Bioscience -- CytRx Corp. -- Exigent International, Inc. -- FutureLink Distribution Corp. -- Hemacare Corporation -- Medarex, Inc. -- Valentis, Inc.

To receive immediate notification of research updates, enter your e-mail address here (ex: name@domain.com):

Advanced Tissue Sciences, Inc.

Advanced Tissue Sciences, Inc. ("ATIS") is a leading tissue engineering company developing living human tissue products for therapeutic applications such as tissue repair and transplants. ATIS has one FDA-approved product (TransCyte™), one product in Phase III clinical trials (Dermagraft®), and a product pipeline that includes tissue engineered cartilage for orthopedic applications, engineered cardiovascular tissues such as blood vessels and heart valves, and products with applications in cosmetic and reconstructive surgery. ATIS has teamed with Smith & Nephew plc, a world leader in wound care, for the commercialization of TransCyte, Dermagraft, and ATIS' cartilage products.

SMALLCAPS RESEARCH

Full Length Report (06/02/99)

Download (MS Word)
Download (MS Word 6)

Financial Model (06/02/99)

Download (MS Excel)

Alliance With INAMED Announced (05/12/99)

Download (MS Word)
Download (MS Word 6)

Initial Opinion (04/07/99)

Download (MS Word)
Download (MS Word 6)